Larazotide

In this phase 2b, double-blind, placebo-controlled trial, 342 adults with celiac disease and persistent symptoms despite a gluten-free diet were randomized to larazotide acetate 0.5, 1, or 2 mg or placebo three times daily for 12 weeks. The 0.5 mg dose met the primary endpoint, significantly reducing symptom severity versus placebo (on-treatment analysis) and producing a 26% relative reduction in symptomatic days and increased proportion of improved days. A non-monotonic dose response was observed, with no benefit at the 1 or 2 mg doses; the drug, a tight-junction regulator acting locally in the gut lumen, was well tolerated with a placebo-like safety profile.

Many people with celiac disease still have belly symptoms even when strictly avoiding gluten. In this large, rigorous study, the lowest dose of larazotide (0.5 mg) eased those lingering symptoms better than a placebo pill, while higher doses did not help. The drug works only inside the gut to help tighten the intestinal lining, and it caused no more side effects than placebo, making it the strongest human evidence to date for the approach.

This randomized, double-blind, placebo-controlled study enrolled 184 patients with controlled celiac disease who underwent a 2.7 g/day gluten challenge for 6 weeks while receiving larazotide acetate (1, 4, or 8 mg three times daily) or placebo. The primary endpoint, change in intestinal permeability by the lactulose-to-mannitol (LAMA) ratio, showed no significant difference between groups. However, larazotide reduced gluten-induced immune activation (attenuated rise in anti-tissue transglutaminase antibodies) and, at the 1 mg dose, significantly reduced gastrointestinal symptom severity compared with placebo.

Researchers deliberately fed gluten to people with celiac disease to see whether larazotide could blunt the reaction. The drug did not change a lab measure of gut leakiness, but it did dampen the immune antibody spike triggered by gluten and, at the lowest dose, reduced digestive symptoms. This supported the idea that the medicine might protect against occasional gluten exposure, though the main barrier-function target was not met.

In this randomized, double-blind, placebo-controlled trial, 86 patients with diet-controlled celiac disease received larazotide acetate (0.25, 1, 4, or 8 mg three times daily) or placebo with a 2.4 g/day gluten challenge for 14 days. High inter-patient variability in the outpatient lactulose-to-mannitol (LAMA) permeability ratio precluded reliable assessment of the primary permeability endpoint. Secondary analyses suggested lower doses limited gluten-induced worsening of gastrointestinal symptom severity and attenuated symptom-associated immune markers; the drug was safe, with headache and urinary tract infection the most common adverse events.

This early, smaller study tested whether larazotide could stop celiac disease from flaring when patients ate gluten for two weeks. The main gut-permeability measurement was too noisy to give a clear answer, but lower doses seemed to reduce the digestive symptoms and immune signs that gluten provokes. The drug was safe overall, and the results helped shape the design of the later, larger trials.